BioCryst (BCRX) director receives RSU and option grants under board plan
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
BIOCRYST PHARMACEUTICALS director Alan G. Levin received equity awards as part of non-employee director compensation. He was granted 15,294 shares of Common Stock as Restricted Stock Units that will vest on the first anniversary of the grant date. He also received an automatic stock option grant for 33,540 shares of Common Stock at an exercise price of $8.5000 per share, expiring on June 11, 2036. Following these awards, he directly holds 79,565 shares of Common Stock.
Positive
- None.
Negative
- None.
Insights
Routine director equity grants align compensation with BIOCRYST share performance.
The filing shows non-employee director Alan G. Levin receiving 15,294 Restricted Stock Units and options for 33,540 shares at an exercise price of $8.5000. Both awards are granted under the company’s Non-Employee Director Compensation Policy.
The RSUs vest on the first anniversary of the grant date, while the options run until June 11, 2036. These awards represent standard, compensation-related acquisitions rather than open-market purchases, so they carry limited signaling value about the director’s independent view of the stock.
Insider Trade Summary
2 transactions reported
Mixed
2 txns
Insider
LEVIN ALAN G
Role
null
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Automatic Stock Option Grant | 33,540 | $0.00 | -- |
| Grant/Award | Common Stock | 15,294 | $0.00 | -- |
Holdings After Transaction:
Automatic Stock Option Grant — 33,540 shares (Direct, null);
Common Stock — 79,565 shares (Direct, null)
Footnotes (1)
- Automatic non-employee director grant of Restricted Stock Units pursuant to the BioCryst Pharmaceuticals, Inc. Non-Employee Director Compensation Policy, as amended (the "Director Compensation Policy"), which will vest on the first anniversary of the date of grant. Automatic non-employee director grant of stock options pursuant to the Director Compensation Policy.
Key Figures
RSU grant: 15,294 shares
Option grant size: 33,540 shares
Option exercise price: $8.5000 per share
+2 more
5 metrics
RSU grant
15,294 shares
Automatic non-employee director Restricted Stock Units grant, vests after one year
Option grant size
33,540 shares
Automatic stock option grant to director on underlying Common Stock
Option exercise price
$8.5000 per share
Exercise price for director stock options granted on June 11, 2026
Option expiration
June 11, 2036
Expiration date of director stock options
Common shares held
79,565 shares
Total Common Stock directly held by director after transactions
Key Terms
Restricted Stock Units, Non-Employee Director Compensation Policy, Automatic Stock Option Grant, stock options
4 terms
Restricted Stock Units financial
"Automatic non-employee director grant of Restricted Stock Units pursuant to the BioCryst Pharmaceuticals, Inc. Non-Employee Director Compensation Policy"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
Non-Employee Director Compensation Policy financial
"pursuant to the BioCryst Pharmaceuticals, Inc. Non-Employee Director Compensation Policy, as amended"
Automatic Stock Option Grant financial
"Automatic non-employee director grant of stock options pursuant to the Director Compensation Policy."
stock options financial
"Automatic non-employee director grant of stock options pursuant to the Director Compensation Policy."
Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.
FAQ
What equity awards did BCRX director Alan G. Levin receive in this Form 4?
Alan G. Levin received 15,294 shares of Common Stock as Restricted Stock Units and an automatic stock option grant for 33,540 shares of Common Stock at an exercise price of $8.5000 per share, as part of BioCryst’s non-employee director compensation.
Are the BCRX equity awards to Alan G. Levin open-market purchases?
No, the equity awards to Alan G. Levin are not open-market purchases. They are automatic grants of Restricted Stock Units and stock options made under BioCryst’s Non-Employee Director Compensation Policy, representing compensation rather than discretionary buying in the market.
When do Alan G. Levin’s BCRX Restricted Stock Units vest?
The 15,294 Restricted Stock Units granted to Alan G. Levin will vest on the first anniversary of the grant date. This one-year vesting schedule comes from BioCryst Pharmaceuticals’ Non-Employee Director Compensation Policy, as described in the Form 4 footnotes.
What are the key terms of Alan G. Levin’s BCRX stock option grant?
Alan G. Levin received an automatic stock option grant for 33,540 shares of BioCryst Common Stock at an exercise price of $8.5000 per share. These options expire on June 11, 2036, providing a long-dated incentive tied to future share performance.
Under what policy were these BCRX director awards granted?
Both the Restricted Stock Units and stock options were granted under BioCryst Pharmaceuticals’ Non-Employee Director Compensation Policy. The policy governs automatic equity awards for non-employee directors, including vesting terms and option grants, as referenced directly in the Form 4 footnotes.